All In MedTech

Device Trial Radar · NCT07600203

Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ

A Double-blind, Placebo-controlled, Randomized Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ Clinical Study Protocol

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 14, 2026

Primary completion

Sep 18, 2026

Study completion Sep 18, 2026

Sponsor

Lead sponsor
Erchonia CorporationNot on our public-company list
Sponsor type
Industry
First posted
May 20, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to determine the effectiveness of the Erchonia EVRL, manufactured by Erchonia Corporation (the Company), in providing temporary relief of nociceptive musculoskeletal chronic jaw pain arising from temporomandibular joint (TMJ).

Conditions

  • TMJ
  • TMJ Pain
  • TMD

Interventions

  • Erchonia® EVRL™Device

    The Erchonia® EVRL™ is a handheld device containing one 635 nm red laser diode and one 405 nm violet laser diode. During treatment, the diodes are positioned approximately 3 to 4 inches from the skin over the temporomandibular joint area. Treatment is administered for a total of 16 minutes, with 8 minutes applied to each side.

  • Placebo DeviceDevice

    The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. During treatment, the diodes are positioned approximately 3 to 4 inches from the skin over the temporomandibular joint area. Treatment is administered for a total of 16 minutes, with 8 minutes applied to each side.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)Time frame: Baseline and immediately after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acton Dental Associates

    Acton, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.